Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
UTMDthis companyUtah Medical Products, Inc.	$71.52	16.08×	1.52×	4.71×	5.61×	29.1%	57.1%	29.6%	29.3%	9.5%	7.6%	7.9%	0×	-5.01×	0×	37.62×	2.2%	4	27.22	4	A
CATXPerspective Therapeutics, Inc.	$0.82	-1.96×	0.98×	0×	-1.74×	-87.1%	0.0%	0.0%	0.0%	-49.8%	-47.2%	-46.9%	0.02×	0.27×	-302.03×	5.17×	0.0%	3	-0.5	3	B-
CHRSCoherus Oncology, Inc.	$0.82	-0.98×	2.8×	4.05×	-0.72×	-124.2%	57.9%	-425.7%	-403.8%	-279.1%	-151.8%	-81.0%	0.66×	0.29×	-19.95×	1.46×	0.0%	2	-12.02	1	C-
INFUInfuSystem Holdings, Inc.	$14.33	28.03×	3.23×	1.29×	7.36×	-53.4%	56.0%	8.3%	4.6%	11.6%	9.3%	8.5%	0.06×	0.01×	9.18×	1.8×	0.0%	9	5.68	3	B+
KRMDKORU Medical Systems, Inc.	$3.08	-101.75×	15.74×	6.52×	-145.65×	-423.5%	62.3%	-7.2%	-6.4%	-15.5%	-14.5%	-0.2%	0.21×	2.98×	0×	2.44×	0.0%	5	8.89	1	C-
OSUROraSure Technologies, Inc.	$3.49	-2.57×	0.52×	1.55×	0.15×	-88.9%	41.9%	-59.2%	-59.8%	-20.2%	-18.6%	-0.0%	0.04×	3.28×	0×	6.58×	0.0%	4	3.11	2	B-
Peer median	—	-1.96×	2.8×	1.55×	-0.72×	-88.9%	56.0%	-7.2%	-6.4%	-20.2%	-18.6%	-0.2%	0.06×	0.29×	0×	2.44×	0.0%	4	3.11	2	—